{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Surgery for GCTB"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Chemotherapy or Other Therapeutic Agents"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Embolization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Interferon"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Radiotherapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"GCTB interventions include: surgery, chemotherapy, embolization, interferon, and radiotherapy.","groups":[{"description":"Participants who received denosumab at the conclusion of Study 20062004 continued in this study (study 20140114), and received denosumab at the current dose (120 mg Q4W SC) and schedule at the investigator's discretion.","id":"OG000","title":"Exposed to IP"},{"description":"Participants who completed denosumab treatment in study 20062004 and were in the safety follow up at the conclusion of study 20062004 continued in long term safety follow up in this study (study 20140114), and did not receive denosumab.","id":"OG001","title":"Not Exposed to IP"}],"paramType":"NUMBER","populationDescription":"FAS included all enrolled participants (from study 20062004) who provided informed consent and had a non-missing enrolment date in this study.","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"Number of Participants Receiving GCTB Interventions","type":"SECONDARY","unitOfMeasure":"Count of Participants"}